Literature DB >> 14708963

Scedosporium species infections and treatments.

W J Steinbach1, J R Perfect.   

Abstract

Scedosporium species are now increasingly isolated from immunocompromised and immunocompetent patients. Unfortunately, Scedosporium species infections are generally resistant to amphotericin B, and S. prolificans strains are particularly resistant to presently-available antifungal agents. Here we review the microbiology, expanding epidemiology, numerous clinical presentations, and diagnostic tools available for Scedosporium species infections. Finally, we detail the available in vitro, animal model, and clinical data on the treatment of Scedosporium species infections with special emphasis on the role of newer antifungal therapies for these recalcitrant infections.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14708963     DOI: 10.1179/joc.2003.15.Supplement-2.16

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  15 in total

1.  Molecular phylogeny of the Pseudallescheria boydii species complex: proposal of two new species.

Authors:  Felix Gilgado; Josep Cano; Josepa Gené; Josep Guarro
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

2.  Infective endocarditis caused by Scedosporium prolificans infection in a patient with acute myeloid leukemia undergoing induction chemotherapy.

Authors:  Yotaro Ochi; Nobuhiro Hiramoto; Hiroshi Takegawa; Noboru Yonetani; Asako Doi; Chihiro Ichikawa; Yukihiro Imai; Takayuki Ishikawa
Journal:  Int J Hematol       Date:  2015-01-29       Impact factor: 2.490

3.  In vitro synergistic interaction between amphotericin B and micafungin against Scedosporium spp.

Authors:  Clara Yustes; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

Review 4.  Combination treatment of invasive fungal infections.

Authors:  Pranab K Mukherjee; Daniel J Sheehan; Christopher A Hitchcock; Mahmoud A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

5.  Prevalence and susceptibility testing of new species of pseudallescheria and scedosporium in a collection of clinical mold isolates.

Authors:  Ana Alastruey-Izquierdo; Manuel Cuenca-Estrella; Araceli Monzón; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2006-11-13       Impact factor: 5.191

6.  Management of Scedosporium apiospermum in a pre- and post-lung transplant patient with cystic fibrosis.

Authors:  Nancy E Rolfe; Tarik J Haddad; Todd S Wills
Journal:  Med Mycol Case Rep       Date:  2013-01-24

Review 7.  Infections caused by Scedosporium spp.

Authors:  Karoll J Cortez; Emmanuel Roilides; Flavio Quiroz-Telles; Joseph Meletiadis; Charalampos Antachopoulos; Tena Knudsen; Wendy Buchanan; Jeffrey Milanovich; Deanna A Sutton; Annette Fothergill; Michael G Rinaldi; Yvonne R Shea; Theoklis Zaoutis; Shyam Kottilil; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

Review 8.  Host immune response against Scedosporium species.

Authors:  Emmanuel Roilides; Maria Simitsopoulou; Aspasia Katragkou; Thomas J Walsh
Journal:  Med Mycol       Date:  2009-01-31       Impact factor: 4.076

9.  Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients.

Authors:  Peter Troke; Koldo Aguirrebengoa; Carmen Arteaga; David Ellis; Christopher H Heath; Irja Lutsar; Montserrat Rovira; Quoc Nguyen; Monica Slavin; Sharon C A Chen
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.191

10.  Molecular typing of Australian Scedosporium isolates showing genetic variability and numerous S. aurantiacum.

Authors:  Laurence Delhaes; Azian Harun; Sharon C A Chen; Quoc Nguyen; Monica Slavin; Christopher H Heath; Krystyna Maszewska; Catriona Halliday; Vincent Robert; Tania C Sorrell; Wieland Meyer
Journal:  Emerg Infect Dis       Date:  2008-02       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.